Literature DB >> 2690302

Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system.

W M Scheld1.   

Abstract

Drug delivery to the central nervous system (CNS) is of vital concern to the therapy for primary CNS disorders and the development of drug neurotoxicity. The factors influencing drug entry into the CSF include the status of the blood-brain barrier (BBB) and lipid solubility, molecular weight, pKa, protein binding, and removal of the drug from the CSF by an exit pump in the choroid plexus. The most important of these factors is the status of the complex BBB systems. The morphologic equivalent of the BBB and its specialized functions (e.g., transport of D-glucose, amino acids, and ions) are discussed in depth. Methods developed for increasing drug delivery to the CNS by circumvention and/or manipulation of the BBB have included direct injection into the CSF, administration of prodrugs or chemical delivery systems, or reversible "opening" of the BBB by hyperosmotic agents, pentylenetetrazole, etoposide, DMSO, or other agents. The relevance of these general principles to selected examples of CNS infections (i.e., gram-negative aerobic bacillary meningitis and subacute encephalopathy associated with AIDS) is emphasized.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690302     DOI: 10.1093/clinids/11.supplement_7.s1669

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  14 in total

1.  Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Authors:  Katherine E Hanlon; Todd W Vanderah
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 2.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Protein therapy using heme-oxygenase-1 fused to a polyarginine transduction domain attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.

Authors:  Tomoyuki Ogawa; Daniel Hänggi; Yumei Wu; Hiroyuki Michiue; Kazuhito Tomizawa; Shigeki Ono; Hideki Matsui; Isao Date; Hans-Jakob Steiger
Journal:  J Cereb Blood Flow Metab       Date:  2011-06-08       Impact factor: 6.200

4.  Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors:  A Ahmed; H Jafri; I Lutsar; C C McCoig; M Trujillo; L Wubbel; S Shelton; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 5.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

6.  Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.

Authors:  Timothy M E Davis; Tran Quang Binh; Kenneth F Ilett; Kevin T Batty; Hoang Lan Phuöng; Gregory M Chiswell; Vu Duong Bich Phuong; Cindy Agus
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 7.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 8.  Transependymal Cerebrospinal Fluid Flow: Opportunity for Drug Delivery?

Authors:  João Casaca-Carreira; Yasin Temel; Sarah-Anna Hescham; Ali Jahanshahi
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

9.  Strategies for enhanced drug delivery to the central nervous system.

Authors:  V S N M Dwibhashyam; A N Nagappa
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

Review 10.  Current approaches to enhance CNS delivery of drugs across the brain barriers.

Authors:  Cui-Tao Lu; Ying-Zheng Zhao; Ho Lun Wong; Jun Cai; Lei Peng; Xin-Qiao Tian
Journal:  Int J Nanomedicine       Date:  2014-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.